Hemogenyx Pharmaceuticals PLC Hemogenyx scientific advisor receives Lasker Award
2019年9月12日 - 3:01PM
RNSニュース (英語)
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
12 September 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Hemogenyx scientific advisor receives Lasker Award
H. Michael Shepard becomes second board member to win
prestigious prize for medical research
Brooklyn, N.Y. - Hemogenyx Pharmaceuticals plc (LSE: HEMO) is
pleased to announce that H. Michael Shepard, a member of
Henogenyx's Scientific Advisory Board, has been awarded the 2019
Lasker-DeBakey Clinical Medical Research Award. The award is given
annually for biological discoveries and clinical advances that
improve human health. The Lasker Awards are America's most
prestigious medical research awards, the US "Nobel". This year's
prize recognizes Dr. Shepard's pivotal role in the invention of
Herceptin, a life-saving therapy for women with breast cancer.
Herceptin is credited with reducing the risk of breast cancer
recurrence and extending the survival time for patients with
metastatic as well as early-stage disease.
In awarding the prize to Dr. Shepard, the Lasker Foundation said
that Shepard's research "executed a new blueprint for drug
discovery that has already bestowed tens of thousands of women with
time and quality of life."
Upon learning of the honor, Dr. Vladislav Sandler, Hemogenyx's
Chief Executive Officer, commented, "We are thrilled that Dr.
Shepard's life-saving work has been recognized by this prestigious
award and we are fortunate to have such a distinguished scientist
advising our own organization's cutting-edge cancer research."
Shepard becomes the second Hemogenyx board member to win the
prestigious prize. In 2003, Chairman of the Board Sir Marc Feldmann
received the Lasker Award for his ground-breaking discovery of
antibodies that block TNF, an effective treatment for rheumatoid
arthritis and other autoimmune diseases.
"Michael Shepard is a pioneering scientist whose research has
improved millions of lives," said Sir Marc. "I'm an admirer of his
achievements and proud to be his friend and have introduced him to
Hemogenyx, where his expertise will help us achieve our goals."
For further information on the award, please follow this
link:
http://www.laskerfoundation.org/awards/show/herceptin-targeted-antibody-therapy-breast-cancer/
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre, Soltan
Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
at its state-of-the-art research facility in New York City and a
wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL,
located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALBMITMBMBBFL
(END) Dow Jones Newswires
September 12, 2019 02:01 ET (06:01 GMT)
Silver Falcon (LSE:SILF)
過去 株価チャート
から 5 2024 まで 6 2024
Silver Falcon (LSE:SILF)
過去 株価チャート
から 6 2023 まで 6 2024